LINC02901: A Potential Drug Target and Biomarker (G100130967)

Target Name: LINC02901

NCBI ID: G100130967

LINC02901

LINC02901: A Potential Drug Target and Biomarker

LINC02901 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in the development and progression of various diseases, including cancer. LINC02901 has been shown to play a role in the regulation of cell proliferation, apoptosis, and angiogenesis, which are critical processes that are involved in the development and progression of many diseases.

The discovery of LINC02901 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. By targeting LINC02901 with drugs, researchers can prevent or reverse the effects of its regulate the cell cycle and apoptosis processes. This can lead to the inhibition of cancer cell growth, regression, and metastasis.

In addition to its potential as a drug target, LINC02901 has also been shown to be a potential biomarker for several diseases. For example, LINC02901 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that LINC02901 may be a useful biomarker for these diseases, as drugs that target LINC02901 may be effective in treating these cancers.

Another potential application of LINC02901 as a drug target and biomarker is its role in the regulation of cellular processes that are important for maintaining tissue homeostasis. LINC02901 has been shown to play a role in the regulation of cell adhesion, which is critical for the maintenance of tissue structure and function.

In addition to its role in cell adhesion, LINC02901 has also been shown to play a role in the regulation of cell migration and the development of cancer. These processes are critical for the development and progression of cancer, and drugs that target LINC02901 may be effective in inhibiting these processes.

The identification of LINC02901 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of LINC02901 in the regulation of cellular processes and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2901

The "LINC02901 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02901 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets